Bullish indicating open at $55-$60, IPO prices at $37
In a recent series of transactions, Larry Heaton, the CEO of Zomedica Corp. (NYSEAMERICAN:ZOM), purchased a significant amount of the company’s common stock. On March 17, 2025, Heaton acquired a total of 500,000 shares, valued at $29,702. The purchase price ranged from $0.054 to $0.06 per share. According to InvestingPro data, this purchase comes as the stock trades with high price volatility, having declined over 33% in the past year.
Following these transactions, Heaton’s total direct ownership in Zomedica increased to 1,000,000 shares. This move underscores the executive’s confidence in the company, which operates in the pharmaceutical preparations sector. InvestingPro analysis indicates the company maintains strong liquidity with cash exceeding debt, though it’s currently experiencing rapid cash burn.
Zomedica, based in Ann Arbor, Michigan, continues to focus on developing innovative solutions in the life sciences industry. Investors will be closely monitoring the company’s performance following this notable insider purchase. For deeper insights into Zomedica’s valuation and 13 additional ProTips, access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Zomedica Pharmaceuticals (NYSE:ZOM) Corp reported its fourth-quarter 2024 earnings, revealing a revenue of $7.9 million, which represents an 8% increase compared to the same period last year. Despite recording a net loss of $7.2 million, the company maintained strong gross margins of 70.3% and a robust cash position with $71.4 million in liquidity. The full-year revenue for 2024 was a record $27.3 million, highlighting the company’s steady growth trajectory. Zomedica’s transition to the OTCQB market followed its delisting from the NYSE American Exchange due to non-compliance with listing standards, although the company continues to focus on driving growth and expanding its product offerings. The company is also exploring various strategic options to address its share price and potentially relist on a major exchange. Zomedica has plans to expand further into the equine market and international territories, aiming for cash flow breakeven at a $50 million run rate. Additionally, the company has signed a significant distribution agreement with Crestlon for the Vetagel hemostatic gel product line, which is expected to contribute to revenue growth in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.